Movie
Story
Daiichi Sankyo RD Novare, a technology-led company
that is the driving force behind new drug discoveries.
As a new challenge, we launched the Clinical Research
Laboratory, which accelerates oncology R&D.
Representative Director
徳井 太郎
TOKUI TARO
The strong desire of Daiichi Sankyo RD Novare employees is
to create drugs that really work for each patient, and to
make as many patients as possible smile with our technology.
To this end, we have begun to take on the challenge of transforming our
drug discovery process.
The application of knowledge and technology developed in
nonclinical research to the analysis of clinical specimens
will provide an accurate understanding of the mechanisms of
disease occurring in humans and lead to drug discovery.
In the future, we aim to become a leading player in the drug
discovery ecosystem by analyzing clinical samples of cancer
in partnership with multiple clinical institutions.
Advantages
The clinical research laboratory began full-scale operations in April 2019.
We invested state-of-the-art technology and equipment to
ensure the reliability of data and information through GCP-
compliant organizational operations.
Vice President
長澤 康男
NAGASAWA YASUO
The main pillar of the clinical research lab is genomics.
By conducting research in collaboration with informatics,
molecular pathology, and genetic analysis, we are able to
achieve multi-layered and highly precise analysis.
We are also focusing on building sophisticated IT systems that
guarantee security and creating a system for GCP compliance.
We believe that we can ensure the reliability of our clinical
research laboratories only by properly processing complexity
and vast amounts of human genome information and handling it
safely in accordance with the Personal Information Protection Law.
centered on genomics
Platforms
Molecular pathology
Analysis of what is happening in the disease lesion site
Molecular Pathology Group
Senior Researcher
小林 真季
KOBAYASHI MAKI
We aim to conduct highly precise clinical research in molecular pathology
by properly handling clinical samples based on histopathological knowledge
of the disease, and by identifying disease areas.
By visualizing changes in the expression and localization of the target molecules,
we analyze what is occurring at the site of the disease.
Visualizing expression changes and localizing target molecules
Genetic analysis
Analysis of gene expression and genetic mutations
in collaboration with molecular pathology
Genomics Group
Scientist
大島 慶子
OSHIMA KEIKO
In genetic analysis, we analyze genetic expression and mutation in collaboration with molecular pathology.
For example, we deepen our understanding of the effects
and side effects of drugs by analyzing cancer tissues
and the microenvironment surrounding the cancer tissues,
and by performing correlative analyses
between histopathology and gene expression.
Bioinformatics Group
Senior Director
岡本 敦之
OKAMOTO ATSUSHI
Genomic analysis of clinical samples is also
the ultimate analysis of personal information.
Therefore, we have built a rigorous and robust system
to properly manage sample tracking and data.
Informatics/Genomics
Towards genomic analysis to understand and
hypothesis disease mechanism
Genomics Group
Senior Director
和田 直也
WADA NAOYA
We are now working to properly process samples on the
basis of such a robust and secure analytical environment,
and to use our diverse genomics analysis methods and
advanced informatics technologies to understand diseases
at the genome and even epigenome levels.
Clinical Research Laboratories, Accelerating Oncology R&D
With a vision of leading clinical research in the oncology
field in Japan, we took a major step forward in the clinical
research lab of Daiichi Sankyo RD Novare.
The ultimate ideal is the realization of
a world that quickly delivers optimal drugs
to each patient waiting for new drugs.
